Track topics on Twitter Track topics that are important to you
Biogen made investors very nervous after it announced that it was choosing to add an additional 510 patients to its key trial into its Alzheimer’s medicine.
The decision to flood more patients into the trial was made after it apparently saw “increased variability” on the data from those receiving aducanumab.
It’s a bad time for potential treatments into Alzheimer’s, with a raft of companies recently throwing in the towel on key drugs since the start of the year and Pfizer surprising the entire industry by dumping its neuroscience division.
Original Article: Biogen shares hit by key Alzheimer’s drug concernsNEXT ARTICLE
Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...